Skip to Content
Merck

I0500000

Isoniazid

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

4-Pyridinecarboxylic acid hydrazide, INH, Isonicotinic acid hydrazide, Isonicotinic hydrazide

Slide 1 of 1
Sign In to View Organizational & Contract Pricing.

Select a Size

Pricing and availability is not currently available.

About This Item

Empirical Formula (Hill Notation):
C6H7N3O
CAS Number:
54-85-3
Molecular Weight:
137.14
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
329815311
MDL number:
MFCD00006426
Beilstein/REAXYS Number:
119374

Key Documents

View All Documentation

Skip To

Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Isoniazid, European Pharmacopoeia (EP) Reference Standard

InChI

1S/C6H7N3O/c7-9-6(10)5-1-3-8-4-2-5/h1-4H,7H2,(H,9,10)

SMILES string

NNC(=O)c1ccncc1

InChI key

QRXWMOHMRWLFEY-UHFFFAOYSA-N

grade

pharmaceutical primary standard

agency

EP Reference Standard

API family

isoniazid

manufacturer/tradename

EDQM

mp

171-173 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

Looking for similar products? Visit Product Comparison Guide

Related Categories

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
BP1083I33778.06753
Isoniazid European Pharmacopoeia (EP) Reference Standard

I0500000

Isoniazid

Isoniazid British Pharmacopoeia (BP) Reference Standard

BP1083

Isoniazid

Isoniazid analytical standard, ≥99% (TLC)

Supelco

I3377

Isoniazid

4-Pyridinecarboxylic acid hydrazide for synthesis

Sigma-Aldrich

8.06753

4-Pyridinecarboxylic acid hydrazide

manufacturer/tradename

EDQM

manufacturer/tradename

BP

manufacturer/tradename

-

manufacturer/tradename

-

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

analytical standard

grade

-

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical
pharmaceutical small molecule

application(s)

forensics and toxicology
pharmaceutical (small molecule)

application(s)

-

format

neat

format

neat

format

neat

format

-

agency

EP Reference Standard

agency

-

agency

-

agency

-

API family

isoniazid

API family

isoniazid

API family

-

API family

-

Application

Isoniazid EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Antibiotic for treatment of Mycobacterium tuberculosis, inhibits mycolic acid biosynthesis. Metabolized by hepatic N-acetyltransferase (NAT) and cytochrome P450 2E1 (CYP2E1) to form hepatotoxins. Selectively induces expression of CYP2E1. Reversibly inhibits CYP2C19 and CYP3A4 activities, and mechanistically inactivates CYP1A2, CYP2A6, CYP2C19 and CYP3A4 at clinically relevant concentrations.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

related product

Product No.
Description
Pricing

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302,H315

Hazard Classifications

Acute Tox. 4 Oral - Skin Irrit. 2

Storage Class

11 - Combustible Solids

wgk

WGK 3

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

A fresh look at the mechanism of isoniazid-induced hepatotoxicity.
I G Metushi et al.
Clinical pharmacology and therapeutics, 89(6), 911-914 (2011-03-18)
Kanchan Ajbani et al.
Antimicrobial agents and chemotherapy, 59(1), 414-420 (2014-11-05)
Reliable molecular diagnostics, which detect specific mutations associated with drug resistance, are promising technologies for the rapid identification and monitoring of drug resistance in Mycobacterium tuberculosis isolates. Pyrosequencing (PSQ) has the ability to detect mutations associated with first- and second-line
Anandi Martin et al.
The Journal of antimicrobial chemotherapy, 62(1), 56-64 (2008-04-15)
The reference standard methods for drug susceptibility testing (DST) of M. tuberculosis are very slow to give results, and due to the emergence of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis, there is an urgent demand for new, rapid and
Laura Muñoz et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 60(3), 349-356 (2014-10-15)
The extent to which anti-tumor necrosis factor (TNF)-associated tuberculosis can be prevented is unclear, and there is no established guidance on the optimal screening strategy for latent tuberculosis (LTBI) in patients about to start anti-TNF therapy. We aimed to determine
Molebogeng X Rangaka et al.
Lancet (London, England), 384(9944), 682-690 (2014-05-20)
Antiretroviral therapy reduces the risk of tuberculosis, but tuberculosis is more common in people with HIV than in people without HIV. We aimed to assess the effect of isoniazid preventive therapy on the risk of tuberculosis in people infected with
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service